Literature DB >> 30692863

Neurostatus and EDSS Calculation with Cases.

Sedat Şen1.   

Abstract

Expanded Disability Status Scale (EDSS) is the most commonly used disability scale for multiple sclerosis (MS) patients. It provides effective and reliable evaluation at every stage of the disease. It is mainly based on the evaluation of functional systems. Neurostatus provides an up-to-date and improved basis for EDSS assessment.

Entities:  

Keywords:  Multiple sclerosis; disability; neurostatus

Year:  2018        PMID： 30692863      PMCID： PMC6278622          DOI： 10.29399/npa.23412

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN： 1300-0667            Impact factor:   1.339


  6 in total

Review 1.  Quantification of impairment in MS: discussion of the scales in use.

Authors:  M P Amato; G Ponziani
Journal:  Mult Scler       Date:  1999-08       Impact factor: 6.312

2.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

3.  A new scale for evaluating disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1955-08       Impact factor: 9.910

4.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

5.  Origin of DSS: to present the plan.

Authors:  J F Kurtzke
Journal:  Mult Scler       Date:  2007-01       Impact factor: 6.312

6.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910
  6 in total
  6 in total

1.  Personality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: A cross-sectional case-control study.

Authors:  Amirali Ghahremani; Sahar Mosa Farkhani; Mahsa Baniasadi; Seyed Kaveh Hojjat; Hasan Namdar Ahmadabad; Davoud Salarbashi; Sepideh Elyasi; Najmeh Davoodian
Journal:  Brain Behav       Date:  2022-04-22       Impact factor: 3.405

Review 2.  Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.

Authors:  Spyros Papapetropoulos; Angela Pontius; Elizabeth Finger; Virginija Karrenbauer; David S Lynch; Matthew Brennan; Samantha Zappia; Wolfgang Koehler; Ludger Schoels; Stefanie N Hayer; Takuya Konno; Takeshi Ikeuchi; Troy Lund; Jennifer Orthmann-Murphy; Florian Eichler; Zbigniew K Wszolek
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

3.  Brain MRI dataset of multiple sclerosis with consensus manual lesion segmentation and patient meta information.

Authors:  Ali M Muslim; Syamsiah Mashohor; Gheyath Al Gawwam; Rozi Mahmud; Marsyita Binti Hanafi; Osama Alnuaimi; Raad Josephine; Abdullah Dhaifallah Almutairi
Journal:  Data Brief       Date:  2022-04-07

4.  Evaluation of the Psychometric Properties of the Health Assessment Questionnaire (HAQ) in a Population of Individuals With Multiple Sclerosis.

Authors:  Anna Berardi; Antonella Conte; Lucilla Cimmino; Carlotta Cimmino; Viola Baione; Sebastiano Giuseppe Crisafulli; Marco Tofani; Matteo Tartaglia; Giovanni Fabbrini; Giovanni Galeoto
Journal:  Front Neurol       Date:  2022-03-28       Impact factor: 4.003

5.  Coping Strategies Furthering Post-Traumatic Growth in Multiple Sclerosis: A Longitudinal Study.

Authors:  Irene Gil-González; Agustín Martín-Rodríguez; Rupert Conrad; María Ángeles Pérez-San-Gregorio
Journal:  Int J Environ Res Public Health       Date:  2022-10-04       Impact factor: 4.614

6.  Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells in Multiple Sclerosis Patients With Older Appearing Brains.

Authors:  Sophie A H Jacobs; Paolo A Muraro; Maria T Cencioni; Sarah Knowles; James H Cole; Richard Nicholas
Journal:  Front Neurol       Date:  2022-01-06       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.